Department of Pharmacology, University of Washington School of Medicine, Seattle, WA 98195-7280, USA.
Mol Pharmacol. 2010 Mar;77(3):339-47. doi: 10.1124/mol.109.060558. Epub 2009 Dec 3.
The effects of phosphorylation of the tyrosine residue in the highly conserved DRY motif expressed in the putative second cytoplasmic loop of the mu-opioid receptor were assessed after expression in human embryonic kidney (HEK) 293 cells. Tyrosine kinase activation by epidermal growth factor (EGF) or hydrogen peroxide treatment effectively increased phosphorylation of the tyrosine-166 in the mu-opioid receptor (MOR-Tyr166p) as measured by a novel phosphoselective antibody. We were surprised to find that the increase in MOR-Tyr166p immunoreactivity (ir) required coactivation by the opioid agonist [D-Ala(2),methyl-Phe(4),Gly(5)-ol]enkephalin (DAMGO), as demonstrated by both Western blot imaging of membrane proteins and confocal microscopy of transfected cells; MOR-Tyr166p-ir did not significantly increase after either DAMGO, EGF, or H(2)O(2) treatment alone. The increase in MOR-Tyr166p-ir was blocked by pretreatment with the opioid antagonist naloxone or the Src kinase inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine. Consistent with these data, mutation of the tyrosine-166 to phenylalanine blocked the increased immunoreactivity, and untransfected HEK293 cells did not increase MOR-Tyr166p-ir after treatment. DAMGO increased guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTP gamma S) binding to membranes from cells expressing wild-type MOR or MOR-Y166F receptors in a dose-dependent manner. Pretreatment of the wild-type MOR-expressing cells with the combination of DAMGO and EGF completely blocked subsequent DAMGO stimulation of [(35)S]GTP gamma S binding membranes, whereas [(35)S]GTP gamma S binding to membranes from cells expressing mutated MOR(Y166F) was only partially inhibited. These results suggest that G-protein activation as measured by [(35)S]GTP gamma S binding can be regulated by DAMGO and EGF by convergent mechanisms and support the hypothesis that tyrosine phosphorylation within the DRY motif may reduce mu-opioid receptor-G-protein coupling efficiency.
在人胚肾 (HEK) 293 细胞中表达后,评估了在假定的 μ-阿片受体第二细胞内环中表达的高度保守 DRY 基序中的酪氨酸残基磷酸化的作用。表皮生长因子 (EGF) 或过氧化氢处理的酪氨酸激酶激活可有效增加 μ-阿片受体 (MOR-Tyr166p) 中酪氨酸-166 的磷酸化,如新型磷酸选择性抗体所测量的那样。我们惊讶地发现,MOR-Tyr166p 免疫反应性 (ir) 的增加需要阿片样激动剂 [D-Ala(2),甲基-Phe(4),Gly(5)-ol]enkephalin (DAMGO) 的共激活,这通过膜蛋白的 Western blot 成像和转染细胞的共聚焦显微镜都得到了证明;MOR-Tyr166p-ir 单独用 DAMGO、EGF 或 H(2)O(2) 处理后并未显著增加。MOR-Tyr166p-ir 的增加被阿片拮抗剂纳洛酮或 Src 激酶抑制剂 4-氨基-5-(4-氯-苯基)-7-(叔丁基)吡唑并[3,4-d]嘧啶预处理所阻断。与这些数据一致,将酪氨酸-166 突变为苯丙氨酸可阻断增加的免疫反应性,并且未转染的 HEK293 细胞在用药物处理后不会增加 MOR-Tyr166p-ir。DAMGO 以剂量依赖的方式增加表达野生型 MOR 或 MOR-Y166F 受体的细胞的膜结合鸟苷 5'-O-(3-[(35)S]硫代)三磷酸 ([(35)S]GTPγS)。用 DAMGO 和 EGF 的组合预处理表达野生型 MOR 的细胞完全阻断了随后 DAMGO 对 [(35)S]GTPγS 结合膜的刺激,而表达突变型 MOR(Y166F)的细胞的 [(35)S]GTPγS 结合膜仅部分被抑制。这些结果表明,如 [(35)S]GTPγS 结合所测量的 G 蛋白激活可以通过 DAMGO 和 EGF 通过会聚机制进行调节,并支持这样的假设,即在 DRY 基序内的酪氨酸磷酸化可能会降低 μ-阿片受体-G 蛋白偶联效率。